NEONATAL MEDICATION PROTOCOLS

SURFACTANT (BOVINE) – BERACTANT (SURVANTA)
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	**SURFACTANT (BOVINE) – BERACTANT (SURVANTA)**
PRESENTATION:	Vial: 8 mL
ACTION & INDICATION:	Pulmonary surfactant derived from natural bovine lung extract and used for the prevention or treatment of respiratory distress syndrome, according to NCCU guidelines.
DOSE:	4 mL/kg/dose Up to four doses may be administered, at 6 hourly intervals.
ADMINISTRATION:	**For intratracheal administration only**. Survanta is administered via a 5fg end hole catheter shortened to protrude just beyond the end of the ETT, above the carina. Survanta should **NOT** be instilled into a **main** stem bronchus. Administer as outlined in the NCCU "Surfactant Replacement Therapy Guidelines".
ADVERSE EFFECTS:	Adverse effects associated with dosing procedure: Transient bradycardia, oxygen desaturation, ETT reflux, pallor, vasoconstriction, hypotension, ETT blockage, hypertension, hypocarbia, hypercarbia, apnoea.
COMMENTS:	Warm vial to room temperature before use. Do not use artificial warming methods. Do not shake. Store open and unopened vials at 2 - 8ºC. Discard 12 hours after opening. Evaluate clinical condition before and for 30 minutes after each dose
REFERENCES:	Neofax 2013
DATE:	October 2013